Transcriptional responses of
BMC Genomics, 2011 Background Burkholderia cenocepacia is a Gram-negative opportunistic pathogen displaying high resistance to antimicrobial peptides and polymyxins. We identified mechanisms of resistance by analyzing transcriptional changes to polymyxin B treatment in ...
Molinaro Antonio +4 more
doaj +3 more sources
Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study [PDF]
Frontiers in Pharmacology, 2018 Polymyxins are currently used as the last-resort antibiotics against multidrug-resistant Acinetobacter baumannii. As resistance to polymyxins emerges in A. baumannii with monotherapy, combination therapy is often the only remaining treatment option.
Thien B. Tran +6 more
doaj +4 more sources
Polymyxin B vs colistin: The comparison of neurotoxic and nephrotoxic effects of the two polymyxins [PDF]
Journal of Global Antimicrobial ResistanceAIM: To compare polymyxin B with colistimethate sodium (CMS) regarding neurotoxicity, nephrotoxicity, and 30-day mortality in patients with multi-drug resistant (MDR) gram-negative.
Pınar Aysert Yıldız +5 more
doaj +3 more sources
Selective Reductive Cleavage of the Threonine 2 Peptide Bond of Penta-N-Boc-Polymyxin B with Sodium Borohydride [PDF]
, 2022 Sodium borohydride surprisingly cleaves the Threonine2 (Thr2) peptide bond in N-protected Polymyxin B. Occurring at 20 ºC, the mild reductive cleavage is novel; and it facilitates the synthesis of PMB-derived antibiotics.
Adriano, Afonso, Jay, Weinstein
core +1 more source
Interactions of polymyxin B with lipopolysaccharide-containing membranes [PDF]
, 2021 Bacterial resistance to antibiotics constantly remodels the battlefront between infections and antibiotic therapy. Polymyxin B, a cationic peptide with an anti-Gram-negative spectrum of activity is re-entering use as a last resort measure and as an ...
Bonev, Boyan B. +2 more
core +2 more sources
Frontiers in Pharmacology, 2022 Background: Polymyxin B has become the last choice for patient with carbapenem-resistant bacterial infection. However, the optimal dosing of polymyxin B in critically ill children receiving continuous renal replacement therapy (CRRT) remains unclear.Case
Caifang Xu +19 more
doaj +1 more source
Polymyxin B-Induced Skin Hyperpigmentation [PDF]
, 2020 Polymyxin B-induced skin hyperpigmentation is a rare adverse drug reaction (ADR). In this report, we present the case of a patient who underwent an abscess resection with right epididymitis, in which a multidrug-resistant Klebsiella pneumoniae infection (
Chunliu Luo, Xueke Wen, Weitao Lyu
core +1 more source
Brazilian Journal of Infectious Diseases, 2019 Polymyxin B is one of the last resort option for carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection in China. Therefore, the timing of administration of polymyxin is frequently delayed.
Qiqiang Liang, Man Huang, Zhijiang Xu
doaj +3 more sources
Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. [PDF]
CPT Pharmacometrics Syst PharmacolPBPK/PD modeling and clinical retrospective validation of intravenous polymyxin B in critically ill patients with pulmonary infection. ABSTRACT Intravenous polymyxin B (PMB) is widely used for treating drug‐resistant gram‐negative pneumonia, though its efficacy in pulmonary infections is considered limited.
Zhang S +9 more
europepmc +2 more sources
Journal of Global Antimicrobial Resistance, 2021 Objectives: The epidemic dimensions of the emergence of multidrug-resistant (MDR) Gram-negative bacterial infections have led to the revival of old antibiotics, including the polymyxins.
Matthew E. Falagas +5 more
doaj +1 more source